Back to Agenda
Session 1, Tracks A, B: Regulatory and Clinical Priorities, Plans, Projects and Updates from Regulatory Authorities
Session Chair(s)
Maria Antonieta Tony Roman, MPharm
Head Regulatory Policy Emerging Markets LATAM
Novartis, Mexico
Michelle Arguelles Gonzalez, MBA, RPh, PMP
Executive Director, Clinical Research
Merck Sharp & Dohme (MSD), Mexico
This session will provide insights and updates from various regulatory health authorities in Latin America on their current regulatory priorities, plans, projects, and updates. Gain a broader understanding of the current regulatory systems in Latin America with both clinical and regulatory perspectives presented.
Learning Objective : At the conclusion of this session, participants should be able to:- Recognize strategies and advances from Rregulatory Aagencies towards strengthening regulatory systems in their respective region
- Describe insights and best practices from regulators
- Define future perspectives, challenges, and opportunities for the regulation of biopharmaceuticals in Latin America
Speaker(s)
Updates from Central America
Noe Geovanni Garcia
National Directorate Of Medicines, El Salvador
National Director
Caribbean Regulatory System Priorities, Updates and Plans
Rian Marie Extavour, PhD, MSc, RPh
Caribbean Public Health Agency (CARPHA), Trinidad And Tobago
Programme Manager, Caribbean Regulatory System
Updates from Chile
Heriberto Enrique García Escorza, MPA, RPh
Instituto de Salud Pública de Chile, Chile
Director
Regulatory Priorities, Plans, Projects and Updates from ANVISA
Daniela Marreco Cerqueira, MS
ANVISA, Brazil
Associate Director, Third Directorate
Have an account?